- Trials with a EudraCT protocol (44)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
44 result(s) found for: Bruton Tyrosine Kinase.
Displaying page 1 of 3.
EudraCT Number: 2021-000715-23 | Sponsor Protocol Number: FIL_COLUMN | Start Date*: 2021-12-14 | |||||||||||
Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS | |||||||||||||
Full Title: Consolidation with ADCT-402 (loncastuximab tesirine) after a short course of immunochemotherapy: a phase II study in BTKi-treated (or BTKi intolerant) Relapsed/Refractory (R/R) Mantle Cell Lymphoma... | |||||||||||||
Medical condition: Bruton Tyrosine Kinase inhibitors (BTKi) treated (or BTKi intolerant) relapsed/refractory (R/R) Mantle Cell Lymphoma (MCL). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-004056-11 | Sponsor Protocol Number: PCI-32765MCL3002 | Start Date*: 2014-01-30 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Bendamustine and Rituximab (BR) in Subjects ... | |||||||||||||
Medical condition: Mantle Cell Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) BE (Completed) GB (GB - no longer in EU/EEA) DE (Ongoing) HU (Completed) IE (Completed) IT (Ongoing) PT (Prematurely Ended) SK (Completed) ES (Ongoing) NL (Ongoing) FR (Completed) PL (Ongoing) CZ (Ongoing) GR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000468-32 | Sponsor Protocol Number: CLSG-MCL-POLA | Start Date*: 2021-09-17 | |||||||||||
Sponsor Name:Kooperativní lymfomová skupina, z.s. | |||||||||||||
Full Title: A phase II, open-label, study of polatuzumab-vedotin in combination with bendamustine and rituximab for patients with mantle cell lymphoma, who relapse after previous therapy with Bruton tyrosine k... | |||||||||||||
Medical condition: Mantle cell lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000959-40 | Sponsor Protocol Number: PCI-32765DBL3001 | Start Date*: 2013-08-02 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vi... | |||||||||||||
Medical condition: Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) SE (Completed) CZ (Completed) DE (Completed) BE (Completed) HU (Completed) ES (Prematurely Ended) FI (Completed) IT (Prematurely Ended) DK (Completed) PL (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000259-28 | Sponsor Protocol Number: 54179060LYM3003 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell non-Hodgkin Lymphoma. | |||||||||||||
Medical condition: Mature B-Cell Neoplasm | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed) BE (Completed) CZ (Completed) HU (Completed) DE (Completed) NL (Completed) ES (Completed) PL (Completed) BG (Completed) Outside EU/EEA SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000601-74 | Sponsor Protocol Number: PCI-32765MCL3001 | Start Date*: 2014-01-24 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Randomized, Controlled, Open-Label, Multicenter Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, Versus Temsirolimus in Subjects with Relapsed or Refractory Mantle Cell L... | |||||||||||||
Medical condition: Relapsed or refractory Mantle Cell Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) BE (Completed) DE (Completed) GB (Completed) IE (Completed) HU (Completed) PT (Completed) CZ (Completed) NL (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000694-23 | Sponsor Protocol Number: PCYC-1112-CA | Start Date*: 2012-08-08 | |||||||||||
Sponsor Name:Pharmacyclics LLC an Abbvie Company | |||||||||||||
Full Title: A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia... | |||||||||||||
Medical condition: relapsed or refractory CLL/SLL | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IE (Completed) PL (Completed) ES (Completed) IT (Completed) AT (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000064-42 | Sponsor Protocol Number: MS200527-0081 | Start Date*: 2016-07-27 | |||||||||||
Sponsor Name:Merck KGaA | |||||||||||||
Full Title: Phase IIa Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of M2951 in Subjects with Rheumatoid Arthritis on Stable Methotrexate Therapy | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) HU (Completed) CZ (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003927-12 | Sponsor Protocol Number: DRI15928 | Start Date*: 2019-03-06 |
Sponsor Name:Genzyme Corporation | ||
Full Title: A Phase 2b dose-finding study for SAR442168, a Bruton's tyrosine kinase inhibitor, in participants with relapsing multiple sclerosis | ||
Medical condition: Relapsing Multiple Sclerosis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Completed) ES (Completed) NL (Completed) SK (Completed) EE (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-006495-16 | Sponsor Protocol Number: PrEPSo | Start Date*: 2022-02-25 | |||||||||||
Sponsor Name:ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE "LAZZARO SPALLANZANI" | |||||||||||||
Full Title: Immunogenicity and safety of Sotrovimab (Vir 7831) IV as primary prophylaxis in anti-SARS-CoV-2 vaccine non responders | |||||||||||||
Medical condition: Covid 19 Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000647-30 | Sponsor Protocol Number: EFC16645 | Start Date*: 2020-08-27 | |||||||||||
Sponsor Name:Genzyme Corporation | |||||||||||||
Full Title: A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with nonrelapsing secondary progressive multiple sclerosis | |||||||||||||
Medical condition: Non-relapsing Secondary Progressive Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Ongoing) DE (Restarted) GB (GB - no longer in EU/EEA) CZ (Ongoing) NO (Temporarily Halted) FI (Ongoing) DK (Ongoing) BE (Ongoing) LT (Ongoing) GR (Ongoing) NL (Restarted) PT (Ongoing) PL (Ongoing) HU (Ongoing) IT (Ongoing) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000645-14 | Sponsor Protocol Number: EFC16035 | Start Date*: 2020-10-13 | |||||||||||
Sponsor Name:Genzyme Corporation | |||||||||||||
Full Title: A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (PERSEUS) | |||||||||||||
Medical condition: Primary Progressive Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) BG (Ongoing) EE (Ongoing) GB (GB - no longer in EU/EEA) DK (Ongoing) NO (Temporarily Halted) CZ (Ongoing) GR (Ongoing) LV (Ongoing) DE (Restarted) BE (Ongoing) HU (Ongoing) NL (Restarted) PT (Ongoing) IT (Ongoing) HR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001448-21 | Sponsor Protocol Number: MS200527-0086 | Start Date*: 2017-02-16 | ||||||||||||||||
Sponsor Name:Merck KGaA | ||||||||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of M2951 with a Parallel, Open-Label, Active Control Group (Tecfidera), in Patients with Relapsing Multiple Sclerosis to Evaluate Effic... | ||||||||||||||||||
Medical condition: Relapsing Multiple Sclerosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SK (Completed) ES (Ongoing) CZ (Ongoing) PL (Ongoing) BG (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003967-23 | Sponsor Protocol Number: PCYC-1115-CA | Start Date*: 2013-02-05 | |||||||||||
Sponsor Name:Pharmacyclics, Incorporated | |||||||||||||
Full Title: A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton’s Tyrosine Kinase Inhibitor PCI-32765 versus Chlorambucil in Patients 65 Years or Older with Treatment-naive Chronic Lymphocytic L... | |||||||||||||
Medical condition: Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) IE (Completed) CZ (Completed) DE (Completed) ES (Completed) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000644-55 | Sponsor Protocol Number: EFC16034 | Start Date*: 2020-12-22 | |||||||||||
Sponsor Name:Genzyme Corporation | |||||||||||||
Full Title: A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio®) in participants with relapsing forms of multiple sclerosis | |||||||||||||
Medical condition: Relapsing Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) DE (Ongoing) GB (GB - no longer in EU/EEA) CZ (Ongoing) LV (Ongoing) SK (Ongoing) BE (Ongoing) NO (Completed) GR (Ongoing) NL (Ongoing) PT (Ongoing) HU (Ongoing) HR (Ongoing) IT (Ongoing) EE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022939-11 | Sponsor Protocol Number: PCYC-1104-CA | Start Date*: 2011-05-17 | ||||||||||||||||
Sponsor Name:Pharmacyclics, Incorporated | ||||||||||||||||||
Full Title: Multicenter phase 2 study of Bruton’s tyrosine kinase (Btk) inhibitor, PCI-32765, in relapsed or refractory mantle cell lymphoma | ||||||||||||||||||
Medical condition: Relapsed or refractory mantle cell lymphoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) DE (Completed) AT (Completed) | ||||||||||||||||||
Trial results: Removed from public view |
EudraCT Number: 2013-003561-34 | Sponsor Protocol Number: PCYC-1121-CA | Start Date*: 2014-01-07 | |||||||||||
Sponsor Name:Pharmacyclics LLC | |||||||||||||
Full Title: A Multicenter, Open-Label, Phase 2 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects with Relapsed/Refractory Marginal Zone Lymphoma | |||||||||||||
Medical condition: Relapsed or refractory marginal zone lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004341-17 | Sponsor Protocol Number: PCYC-1123-CA | Start Date*: 2014-10-16 | |||||||||||
Sponsor Name:Pharmacyclics LLC | |||||||||||||
Full Title: A Multicenter Open-Label Phase 1b/2 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse... | |||||||||||||
Medical condition: Relapsed or Refractory Diffuse Large B-Cell Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003093-27 | Sponsor Protocol Number: PCI-32765FLR3001 | Start Date*: 2013-12-18 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination with Either Bendamustine and Rituximab (BR) or Rituxim... | |||||||||||||
Medical condition: Indolent Non-Hodgkin Lymphoma (iNHL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) BE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) IT (Completed) DE (Completed) PL (Completed) FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-006475-42 | Sponsor Protocol Number: ICP-CL-00107 | Start Date*: 2022-06-15 | |||||||||||
Sponsor Name:InnoCare Pharma Inc. | |||||||||||||
Full Title: A Phase I/II, Multicenter, Open-Label, Study of a Novel Bruton’s Tyrosine Kinase Inhibitor, Orelabrutinib, in Patients with B-Cell Malignancies | |||||||||||||
Medical condition: B-cell malignancies, including only patients with Grades 1-3a FL, MZL, MCL, and CLL/SLL | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.